|
|
Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Research
General Research
- Non-Nucleoside Reverse Transcriptase Inhibitors in Development (October 11, 2009)
To read PDF, click here
From AIDS InfoNet
- When HIV Regimens Fail, Resistance Risk Appears Higher on NNRTIs Than Protease Inhibitors (October 3, 2008)
From aidsmap.com
- Drug Watch: Next-Generation NNRTIs: Etravirine and Rilpivirine (Winter 2008)
To read PDF, click here
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- NNRTIs: The Next Generation Approaches (Part I) (December 14, 2006)
From The Body PRO
- NNRTIs: The Next Generation Approaches (Part II) (December 14, 2006)
From The Body PRO
- People With History of Depression More Likely to Stop Efavirenz Due to Mental Health Problems (July 26, 2006)
From aidsmap.com
- HIV JournalView: Adherence, Viral Fitness and NNRTI and PI Resistance (February/March 2006)
Bangsberg et al find that NNRTIs are more likely to suppress HIV than a single PI, but are also more vulnerable to resistance at low adherence levels.
From The Body PRO
- HIV JournalView: Dosing Adjustment Likely Needed for Statins Taken With NNRTIs (January 2006)
[Archived Article]
Part of David Wohl, M.D.'s review of the top 10 HIV research reports of 2005.
In HIV JournalView, from The Body PRO
- HIV JournalView: Low-Level Viremia May Slowly Breed Resistance, but Watch Out for NNRTIs (January 2006)
Part of David Wohl, M.D.'s review of the top 10 HIV research reports of 2005.
In HIV JournalView, from The Body PRO
- News Flash!! Once-a-Day Triple NRTI Warning (October 27, 2003)
[Archived Article]
To read PDF, click here
In STEP Ezine, from Seattle Treatment Education Project
- New Anti-HIV Therapies: New NNRTIs (January 2003)
[Archived Article]
From Project Inform
- The Clinical Relevance of Non-Nucleoside Reverse Transcriptase Inhibitor Hypersusceptibility: A Prospective Cohort Analysis (July 11, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
- In Routine Practice, the Durability of First-Line HAART Is Better for NNRTI Than PI-Based Regimens, Regardless of Baseline HIV Status (July 9, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
- New Insights Into Mechanisms of HIV-1 Resistance to Reverse Transcriptase Inhibitors (February 27, 2002)
[Archived Article]
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Distinguishable Lipid Profiles Between PI and NNRTI Therapy May Carry Different Risk of Cardiovascular Disease (CVD) (February 25, 2002)
[Archived Article]
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Associations Between Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Use and HIV-Associated Lipodystrophy Syndrome (HALS) in the Dagna-LipART Cohort Study (October 29, 2001)
[Archived Article]
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO
- Experimental NNRTI Drugs (Spring 2001)
[Archived Article]
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- Safety of Non-PI-containing Regimens in People With High Viral Loads (August 17, 2000)
[Archived Article]
In STEP Ezine, from Seattle Treatment Education Project
- Patient Adherence With Twice-Daily Dosing of Nelfinavir Equivalent to NNRTIs When Given in Combination With Dual NRTIs (July 13, 2000)
[Archived Article]
In The XIII International AIDS Conference, from The Body PRO
- Primary Infection with HIV-1 with Reduced Drug Susceptibility Does Not Appear to Result from Point Source Transmission (January 31, 2000)
[Archived Article]
In The 7th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Reduced Susceptibility to NRTI Is Associated With NNRTI Hypersensitivity in Virus From HIV-1-Infected Patients (January 31, 2000)
[Archived Article]
From Seattle Treatment Education Project
- Trials & Errors: Studies Look at Which Combinations Are Better (February 1999)
[Archived Article]
Clinical trials using NNRTIs with or instead of protease inhibitors.
From Seattle Treatment Education Project
Efavirenz (Sustiva, Stocrin)
- Sustiva + Ginkgo: Possible Recipe for Resistance, Doctors Report (May 21, 2009)
From aidsmap.com
- Jens Lundgren, M.D., Discusses New Findings Regarding MI Risk of Specific Antiretrovirals (February 9, 2009)
The latest data from D:A:D indicate that lopinavir/ritonavir does increase myocardial infarction risk, but efavirenz, nevirapine and tenofovir do not. In this interview, Jens Lundgren, M.D., and HIV advocate Jeff Berry take part in a fascinating discussion on the new findings and their possible underlying causes.
In The 16th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Efavirenz Significantly Reduces Levels of Some Oral Contraceptives (November/December 2008)
In HIV Treatment Bulletin, from HIV i-Base
- Switch to Viramune Safe for Some Who Can't Tolerate Sustiva (December 2008)
To read PDF, click here
In Project Inform Perspective, from Project Inform
- Combining Sustiva + Viread May Increase Liver Risk, Case Reports Suggest (May 9, 2008)
In aidsmap.com
- Sustiva Study Finds Ethnicity, Quality of Life Predict Treatment Outcomes (April 1, 2008)
From Project Inform
- High LDL Cholesterol Levels May Drop by Switching Sustiva to Viramune, Study Says (June 12, 2007)
From AIDSMeds.com
- Metabolic Complications: A CROI Round-Up (February 28, 2007)
Includes an analysis of research examining lopinavir/ritonavir vs. efavirenz, the use of growth hormone releasing factor to treat fat gain, the link between cardiovascular disease and HIV treatment, the use of ezetimibe (a choleserol-reducing agent) and the latest on bone health in HIV-infected patients.
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Baseline NNRTI Resistance and Virologic Failure in Treatment-Naive Patients on Efavirenz: An Interview With Daniel Kuritzkes, M.D. (February 26, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Efavirenz-Based Regimens Best Lopinavir/Ritonavir Regimens in Head-to-Head Trial (August 17, 2006)
In XVI International AIDS Conference
- ACTG 384 Substudy: DEXA Outcomes in Antiretroviral-Naive Patients Randomized to Efavirenz or Nelfinavir or Both Plus Nucleoside Backbone (August 16, 2006)
In XVI International AIDS Conference
- Data Supports Bioequivalence for Once-Daily, Single-Pill, Fixed-Dose Combination of Sustiva and Truvada, Drug Companies Announce (January 9, 2006)
Filing of a new drug application is expected in the second quarter of 2006.
To read PDF, click here
From Bristol-Myers Squibb Company and Gilead Sciences, Inc.
- HIV JournalView: Dosing Adjustment Likely Needed for Statins Taken With NNRTIs (January 2006)
[Archived Article]
Part of David Wohl, M.D.'s review of the top 10 HIV research reports of 2005.
In HIV JournalView, from The Body PRO
- HIV JournalView: Efavirenz Has No Significant, Lasting Impact on Neuropsychological Performance (January 2006)
Part of David Wohl, M.D.'s review of the top 10 HIV research reports of 2005.
In HIV JournalView, from The Body PRO
- Higher Efavirenz Plasma Levels May Increase Neuropsychiatric Complication Risk (December 15, 2005)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Efavirenz Clearance May Take Up to 8 Weeks, Case Report Warns; Implications for Treatment Interruption (September 28, 2005)
[Archived Article]
From aidsmap.com
- Gilead's Fixed-Dose Combination of Truvada + Efavirenz Not Yet Bioequivalent to Drugs Alone (August 10, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Head-to-Head Comparison of Three Backbone Regimens With Efavirenz (July 27, 2005)
[Archived Article]
Although this study finds no clear winner, the abacavir + ddI arm appears to fall a bit short.
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
- Efavirenz Reduces Plasma Levels of Popular Statins (July/August 2005)
[Archived Article]
From The Body PRO
- Neuropsychiatric Symptoms From Efavirenz Not Always Time-Limited (May/June 2005)
[Archived Article]
More than half of 120 Spanish patients report persistent, though usually mild, symptoms after nearly two years.
From The Body PRO
- Dual NRTI Plus Efavirenz Regimen Superior to Boosted PI Plus Efavirenz (February 25, 2005)
[Archived Article]
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Multi-National Trial Confirms Superiority of 3-Drug Regimen Containing Efavirenz for the Treatment Naive (February 25, 2005)
[Archived Article]
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- The Genomics of Efavirenz Toxicity (January 2005)
[Archived Article]
Part of HIV JournalView's Top 10 Research Reports of 2004.
In The 12th International AIDS Conference, from The Body PRO
- Atazanavir Has Similar Efficacy, Safety to Efavirenz (August 2, 2004)
[Archived Article]
Unlike most protease inhibitors, atazanavir appears not to increase cholesterol, triglycerides or blood-sugar levels, potentially making it a more attractive option for people at risk of developing cardiovascular disease, a Phase III study finds.
From aidsmap.com
- Tenofovir and Efavirenz Show Promise as Two-Drug Maintenance Regimen (July 26, 2004)
[Archived Article]
The so-called "COOL Study" examined this novel two-drug regimen in patients who had already achieved viral suppression on traditional, three-drug HAART.
From aidsmap.com
- HDL Benefit Is Maintained With Extension of Nevirapine and Efavirenz Treatment in 2NN Study (July 14, 2004)
[Archived Article]
In The XV International AIDS Conference, from The Body PRO
- Genetics, Race/Ethnicity and Efavirenz Side Effects (July 2004)
[Archived Article]
A study finds that a genetic variation, more common among African Americans than whites, impacts the body's absorption of efavirenz.
To read PDF, click here
In Project Inform Perspective, from Project Inform
- Some Reverse Transcriptase Mutations May Increase Susceptibility to Efavirenz-Based Regimens (July 2004)
[Archived Article]
Abstract of a study published in the Journal of Infectious Diseases.
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- Triple-Nucleoside Regimens Versus Efavirenz-Containing Regimens for the Initial Treatment of HIV-1 Infection (April 29, 2004)
[Archived Article]
Abstract of results from ACTG 5095, finding Trizivir (AZT/3TC/abacavir) to be far less effective at suppressing viral load than regimens consisting of efavirenz (Sustiva) plus two or three NRTIs.
In New England Journal of Medicine
- Efavirenz and Nevirapine Keep Going, and Going and Going ... (March/April 2004)
[Archived Article]
Efavirenz and nevirapine may persist in the body longer than was originally thought according to two studies presented at CROI 2004.
In Positively Aware, from Test Positive Aware Network
- Efavirenz May Reduce Blood Levels of Cholesterol Drugs (March/April 2004)
[Archived Article]
A study presented at CROI 2004 suggests an interaction between efavirenz and simvastatin (Zocor) or atorvastatin (Lipitor).
In Positively Aware, from Test Positive Aware Network
- Neurologic Side Effects of Efavirenz Not Affected by the Drug's Blood Levels (March/April 2004)
[Archived Article]
In Positively Aware, from Test Positive Aware Network
- Substudy of 2NN Shows Nevirapine and Efavirenz to Be Equal in Potency (February 9, 2004)
[Archived Article]
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- NNRTI Therapy Associated With Better Sexual Satisfaction (January 6, 2004)
[Archived Article]
From aidsmap.com
- Mother-to-Child Transmission: How Will AZT and Nevirapine Use for MTCT Affect Future Treatment? (Winter 2003/2004)
[Archived Article]
To read PDF, click here
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- Efavirenz or Nevirapine Regimens Are More Potent Than Trizivir for Initial Therapy (September 15, 2003)
[Archived Article]
A 100-patient Spanish study confirms the findings of ACTG 5095.
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- No Detectable Difference in Efficacy Seen Between Efavirenz and Nevirapine (September 15, 2003)
[Archived Article]
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- Treatment Regimens Containing Efavirenz, Nevirapine or Kaletra Are the Most Potent Options for Patients Starting Therapy (September 15, 2003)
[Archived Article]
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- Trizivir Plus Efavirenz Potent for Naive Patients With Low CD4 Counts and High Viral Loads (September 15, 2003)
[Archived Article]
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- Substitution of Nevirapine, Efavirenz, or Abacavir for Protease Inhibitors in Patients With Human Immunodeficiency Virus Infection (September 11, 2003)
[Archived Article]
In The New England Journal of Medicine
- A Randomized Trial of 2 Different 4-Drug Antiretroviral Regimens Versus a 3-Drug Regimen, in Advanced Human Immunodeficiency Virus Disease (September 1, 2003)
[Archived Article]
Patients with advanced HIV are found to benefit the most from HAART regimens containing efavirenz (Sustiva), as opposed to regimens containing nelfinavir (Viracept) or no NNRTI at all.
In Journal of Infectious Diseases
- Low-Level Resistance and Minority Populations: Cross-Resistance Between Nevirapine and Efavirenz (August/September 2003)
[Archived Article]
Once an NNRTI-based regimen fails, no other NNRTIs will work any better, two studies suggest.
In Treatment Bulletin, from HIV i-Base
- Little Lipodystrophy Seen With Either Atazanavir or Efavirenz (July 16, 2003)
[Archived Article]
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- ACTG 5095: Efavirenz-Based Regimens Outperform Triple Nucleoside Combination (July 14, 2003)
[Archived Article]
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- ACTG 5097s: Efavirenz-Related CNS Events in the 5095 Study (July 14, 2003)
[Archived Article]
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Another Look at Induction Maintenance Therapy (July 14, 2003)
[Archived Article]
48-week data on Trizivir and efavirenz in treatment-naive patients.
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Better Suppression, Adherence With Once-Daily FTC/ddI/Efavirenz Than Most PI-Based Regimens (July 14, 2003)
[Archived Article]
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Efavirenz-Based HAART Outperforms a Triple Nucleoside Regimen in Clinical Practice (July 14, 2003)
[Archived Article]
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- IATEC Presents the 2NN Study Results (July 14, 2003)
[Archived Article]
To read PDF, click here
In STEP Ezine, from Seattle Treatment Education Project
- Nevirapine- Versus Efavirenz-Containing Three-Drug Regimens (July 14, 2003)
[Archived Article]
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- The Buzz: Anatomy of a Study -- Trizivir vs. Sustiva (May/June 2003)
[Archived Article]
A closer look at ACTG 5095, which examined the use of Trizivir and efavirenz in several first-line treatment regimens.
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
- Efavirenz More Durable Than Nevirapine, But CNS Toxicity Underestimated (April 29, 2003)
[Archived Article]
British researchers find that efavirenz works better over the long term, but that its psychiatric side effects persist a lot longer than previously thought.
From aidsmap.com
- Who Won 2NN? You (April 2003)
[Archived Article]
A summary of the 2NN study presented at CROI 2003.
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- Trizivir-Only Arm Closed in PI-Sparing, Naive Therapy Trial (March 10, 2003)
[Archived Article]
Important interim results from a Phase III, randomized, double-blind comparison of three protease-inhibitor-sparing regimens for the initial treatment of HIV infection (AACTG Protocol A5095).
To read PDF, click here
From U.S. National Institute of Allergy and Infectious Diseases
- Results of the 2NN Study: A Randomized Comparative Trial of First-Line Antiretroviral Therapy With Regimens Containing Either Nevirapine Alone, Efavirenz Alone or Both Drugs Combined, Together With Stavudine and Lamivudine (February 14, 2003)
[Archived Article]
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Lipid Changes in a Randomized Comparative Trial of First-Line Antiretroviral Therapy With Regimens Containing Either Nevirapine Alone, Efavirenz Alone or Both Drugs Combined, Together With Stavudine and Lamivudine (2NN Study) (February 13, 2003)
[Archived Article]
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Research From the 42nd ICAAC: Atazanavir (December 2002)
[Archived Article]
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- Research From the 42nd ICAAC: Two PIs vs. Two PIs vs. Efavirenz (December 2002)
[Archived Article]
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- Shift in HIV-1 Resistance After Treatment Interruption in Patients With Virological Failure and Antiviral Effect Following Trizivir Plus Efavirenz (AZLF3003 Study) (November 19, 2002)
[Archived Article]
In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO
- Prospective Study of Regional Body Composition in Antiretroviral-Naive Subjects Randomized to Receive Zidovudine + Lamivudine or Didanosine + Stavudine Combined With Nelfinavir, Efavirenz or Both: A5005s, a Substudy of ACTG 384 (September 25, 2002)
[Archived Article]
In 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO
- Efavirenz Long-Term Side Effects (August 9, 2002)
[Archived Article]
From Canadian AIDS Treatment Information Exchange
- Efficacy and Safety of Tenofovir Disoproxil Fumarate Versus Stavudine When Used in Combination With Lamivudine and Efavirenz in HIV-1 Infected Patients Naive to Antiretroviral Therapy: 48-Week Interim Results (July 12, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
- Switching Protease Inhibitors to Nevirapine, Efavirenz or Abacavir: A Randomized, Multicenter, Open-Label, Simplification Trial (July 10, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
- Abacavir/Lamivudine in Combination With Efavirenz, Amprenavir/Ritonavir or Stavudine: ESS40001 (CLASS) Preliminary 48-Week Results (July 9, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
- Resistance Profiles at Baseline and Following Virologic Failure for Subjects Randomized to Receive Abacavir/Efavirenz/Didanosine +/-; Hydroxyurea After Failing Initial NRTI +/- PI Therapy (July 9, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
- Quality of Life, Emotional Status, and Adherence of HIV-1-Infected Patients Treated With Efavirenz Versus Protease Inhibitor-Containing Regimens (April 15, 2002)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Switching Protease Inhibitors to Nevirapine (NEV), Efavirenz (EFA) or Abacavir (ABA): A Randomized, Multicenter, Open-Label, Simplification Trial (February 28, 2002)
[Archived Article]
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- An Assessment of Plasma Amprenavir (APV) Pharmacokinetics (PK) Following Administration of Two GW433908 (908) and Ritonavir (RTV) Regimens in Combination With Efavirenz (EFV) in Healthy Adult Subjects (APV10010) (February 27, 2002)
[Archived Article]
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- A Randomized Trial of Metabolic and Body Composition Changes in Patients Switching from PI-Containing Regimens to Abacavir (ABC), Efavirenz (EFV) or Nevirapine (NVP) (February 26, 2002)
[Archived Article]
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- ACTG 388 Results Indicate Efavirenz-Containing Regimen Superior (February 26, 2002)
[Archived Article]
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Efavirenz Helps Get Rid of Kaposi's Sarcoma (February 14, 2002)
[Archived Article]
From Canadian AIDS Treatment Information Exchange
- Birth Defect in Baby Born to Efavirenz User (February 6, 2002)
[Archived Article]
From Canadian AIDS Treatment Information Exchange
- Virologic Response to Abacavir/Efavirenz/ddI + Hydroxyurea in Subjects Failing Initial NRTI + PI Therapy (NZTA4008 Study) (December 18, 2001)
[Archived Article]
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- Once-Daily Combination Therapy with Emtricitabine, Didanosine and Efavirenz in Treatment-Naive HIV-Infected Adults: 24-Month Follow-Up of the ANRS 091 Trial (October 30, 2001)
[Archived Article]
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO
- Lack of Clinically Relevant Drug-Drug Interactions Between Tenofovir DF and Efavirenz, Indinavir, Lamivudine and Lopinavir/Ritonavir in Healthy Subjects (October 29, 2001)
[Archived Article]
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO
- Minor Interaction Between Efavirenz and Saquinavir When Combined With Small Doses of Ritonavir in a QD Regimen (October 28, 2001)
[Archived Article]
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO
- The Compact Quad, Combivir/Abacavir/Efavirenz -- Preliminary 48-Week Results (October 27, 2001)
[Archived Article]
In 39th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
- Nelfinavir, Efavirenz, or Both After the Failure of Nucleoside Treatment of HIV Infection (August 9, 2001)
[Archived Article]
In New England Journal of Medicine
- Does Efavirenz (Sustiva) Cause Breast Enlargement? (August 1, 2001)
[Archived Article]
From Canadian AIDS Treatment Information Exchange
- Genetic Correlates of Phenotypic Hypersusceptibility to Efavirenz (EFV) in Highly Nucleoside-Experienced Subjects in ACTG 364 (July 10, 2001)
[Archived Article]
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Efavirenz (EFV)-Containing Antiretroviral (ARV) Therapy (T) Effectively Reduces HIV RNA in the Seminal Plasma (SP) of HIV-1-Infected Men (M) (February 7, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Pharmacologic Characteristics of Efavirenz and Nelfinavir Associated With Virologic Response in HIV-Infected Children (February 5, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Successful Substitution of Protease Inhibitors With Efavirenz (EFV) in Patients With Undetectable Viral Loads -- A Prospective, Randomized, Multicenter, Open-Label Study (DMP 049) (February 5, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Evaluation of Novel Combination of Abacavir, Lamivudine and Efavirenz (July 12, 2000)
[Archived Article]
In The XIII International AIDS Conference, from The Body PRO
- PROTRA Study: To Evaluate the Safety and Efficacy of Abacavir and Efavirenz When Substituted for a PI in HIV-1-Infected Subjects Treated With Two NRTIs and a PI With Plasma HIV-RNA Levels Below the Limit of Assay Quantification (July 11, 2000)
[Archived Article]
In The XIII International AIDS Conference, from The Body PRO
- Therapeutic Drug Monitoring of Amprenavir Combined With Ritonavir as Salvage Therapy in HIV-1-Infected Patients (July 11, 2000)
[Archived Article]
In The XIII International AIDS Conference, from The Body PRO
- Efficacy of Efavirenz (Sustiva) Concerning Regimens in Patients With Baseline Plasma HIV-1 RNA Viral Load Exceeding 100,000 copies/mL (February 2, 1999)
[Archived Article]
In The 6th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Summary of Pharmacokinetic Drug Interaction Studies With Efavirenz (November 14, 1998)
[Archived Article]
In The 36th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
- Study Shows Efavirenz Promising in Treating Pediatric HIV Infection (September 28, 1998)
[Archived Article]
Leads to approval of new drug for treating HIV-infected children.
From U.S. National Institute of Allergy and Infectious Diseases
- Efavirenz (Sustiva™) May Equal or Exceed Protease Inhibitor in Initial Antiretroviral Combination (July 17, 1998)
[Archived Article]
From AIDS Treatment News
- A Phase III, Double-Blind, Placebo-Controlled, Multi-Center Study to Determine the Effectiveness and Tolerability of the Combination of Efavirenz and Indinavir (IDV) Versus Indinavir in HIV-1 Infected Patients Receiving Nucleoside Analogue (NRTI) Therapy (June 30, 1998)
[Archived Article]
In The 12th International AIDS Conference, from The Body PRO
- More on Efavirenz (June 30, 1998)
[Archived Article]
In The 12th International AIDS Conference, from The Body PRO
- Still More on Efavirenz (June 30, 1998)
[Archived Article]
In The 12th International AIDS Conference, from The Body PRO
- Durable Clinical Anti-HIV-1 Activity (72 Weeks) and Tolerability for Efavirenz (DMP 266) in Combination With Indinavir (IDV) (June 29, 1998)
[Archived Article]
In The 12th International AIDS Conference, from The Body PRO
- Efavirenz (Sustiva, DMP 266) and Saquinavir (Fortovase) Combination: Pharmacologic Interaction (June 5, 1998)
[Archived Article]
From AIDS Treatment News
- Efavirenz + Indinavir (February 4, 1998)
[Archived Article]
In The 5th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- DMP-266 Resistance, Interactions, and Clinical Efficacy (September 28-October 1, 1997)
[Archived Article]
In The 37th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- Efavirenz (SUSTIVA, Formerly DMP-266) 48-Week Data Announced (September 19, 1997)
[Archived Article]
From AIDS Treatment News
- Impact of DMP-266, A New, Unapproved NNRTI, With Indinavir, and D4T (September 1997)
[Archived Article]
In The 35th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
Nevirapine (Viramune)
- Nevirapine Matches Atazanavir/Ritonavir in 48-Week Study (July 29, 2009)
Nevirapine has equivalent efficacy to atazanavir/ritonavir when combined with tenofovir and emtricitabine in treatment-naive patients, results from the ARTEN study show.
From aidsmap.com
- Nevirapine Sports Better Lipid Profile Than Atazanavir, Study Suggests (July 20, 2009)
Patients taking nevirapine may have a lower risk of developing cardiovascular disease than those taking ritonavir-boosted atazanavir, according to a 569-patient study by European researchers. The study found that although nevirapine's efficacy was non-inferior to that of atazanavir, nevirapine appeared to have a more favorable lipid profile.
In Kaiser Daily U.S. HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Jens Lundgren, M.D., Discusses New Findings Regarding MI Risk of Specific Antiretrovirals (February 9, 2009)
The latest data from D:A:D indicate that lopinavir/ritonavir does increase myocardial infarction risk, but efavirenz, nevirapine and tenofovir do not. In this interview, Jens Lundgren, M.D., and HIV advocate Jeff Berry take part in a fascinating discussion on the new findings and their possible underlying causes.
In The 16th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Switch to Viramune Safe for Some Who Can't Tolerate Sustiva (December 2008)
To read PDF, click here
In Project Inform Perspective, from Project Inform
- High LDL Cholesterol Levels May Drop by Switching Sustiva to Viramune, Study Says (June 12, 2007)
From AIDSMeds.com
- Nevirapine-Associated Toxicity Less Frequent in Non-Naive Patients (August 17, 2006)
In XVI International AIDS Conference
- Hepatotoxicity in IDUs and Non-IDUs Receiving Nevirapine-Based HAART (August 16, 2006)
In XVI International AIDS Conference
- Nevirapine Resistance May Persist in Some Pregnant Women, Study Finds (May 3, 2006)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- In Uganda, Three-NRTI Regimen Including Abacavir Is Better Tolerated Than Nevirapine-Based Regimen (February 7, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections
- HIV JournalView: Dosing Adjustment Likely Needed for Statins Taken With NNRTIs (January 2006)
[Archived Article]
Part of David Wohl, M.D.'s review of the top 10 HIV research reports of 2005.
In HIV JournalView, from The Body PRO
- More Questions Than Answers Regarding High Hepatic Event Rates Among Thai Patients in 2NN Study (December 17, 2005)
[Archived Article]
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
- Therapeutic Drug Monitoring Study Finds Adequate Drug Levels for Once-Daily Nevirapine (July 27, 2005)
[Archived Article]
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
- The Relevance of Host Genotype on Nevirapine Drug Levels (February 23, 2005)
[Archived Article]
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Warning on Two Specific 3-Drug Regimens: Viread + Videx + Either Sustiva or Viramune (November 23, 2004)
[Archived Article]
A brief comment on the recently issued warning that both regimens frequently fail.
In AIDS Treatment News, from AIDS Treatment News
- Addition of Short-Course Zidovudine/Lamivudine to Single-Dose Nevirapine Decreases Development of Maternal NNRTI-Resistant HIV (July 15, 2004)
[Archived Article]
In The XV International AIDS Conference, from The Body PRO
- A HAART Regimen With Lower Metabolic Effect: Nevirapine Plus Non-Thymidine Analog NRTIs (July 14, 2004)
[Archived Article]
In The XV International AIDS Conference, from The Body PRO
- Confort Study Supports Switch From Protease Inhibitor to Nevirapine (July 14, 2004)
[Archived Article]
In The XV International AIDS Conference, from The Body PRO
- HDL Benefit Is Maintained With Extension of Nevirapine and Efavirenz Treatment in 2NN Study (July 14, 2004)
[Archived Article]
In The XV International AIDS Conference, from The Body PRO
- Pregnancy: Severe Liver Toxicity in Nevirapine-Based HAART (June 21, 2004)
[Archived Article]
From aidsmap.com
- Washington Post Profiles South African Program Using Nevirapine to Reduce Risk of Mother-to-Child HIV Transmission (June 9, 2004)
[Archived Article]
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Efavirenz and Nevirapine Keep Going, and Going and Going ... (March/April 2004)
[Archived Article]
Efavirenz and nevirapine may persist in the body longer than was originally thought according to two studies presented at CROI 2004.
In Positively Aware, from Test Positive Aware Network
- Nevirapine Well Tolerated in HIV-Infected Pregnant Women (February 11, 2004)
[Archived Article]
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Substudy of 2NN Shows Nevirapine and Efavirenz to Be Equal in Potency (February 9, 2004)
[Archived Article]
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Nevirapine Should Not Be Used for PEP, Confirms U.S. Review (February 2, 2004)
[Archived Article]
From aidsmap.com
- Nevirapine Hepatotoxicity Risks Clarified in New Letter to Healthcare Professionals (PDF) (February 2004)
[Archived Article]
From Boehringer Ingelheim
- NNRTI Therapy Associated With Better Sexual Satisfaction (January 6, 2004)
[Archived Article]
From aidsmap.com
- Mother-to-Child Transmission: How Will AZT and Nevirapine Use for MTCT Affect Future Treatment? (Winter 2003/2004)
[Archived Article]
To read PDF, click here
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- NNRTI-Based HAART Associated With Quicker CD4 Cell Gains Than PI-Based Therapy (November 13, 2003)
[Archived Article]
Most of the patients in this large but non-randomized Canadian study were taking nevirapine (Viramune).
In The XIII International AIDS Conference, from aidsmap.com
- Efavirenz or Nevirapine Regimens Are More Potent Than Trizivir for Initial Therapy (September 15, 2003)
[Archived Article]
A 100-patient Spanish study confirms the findings of ACTG 5095.
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- No Detectable Difference in Efficacy Seen Between Efavirenz and Nevirapine (September 15, 2003)
[Archived Article]
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- Switching From PI to Nevirapine in Patients With Undetectable Viral Load Is Safe and Potent (September 15, 2003)
[Archived Article]
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- Treatment Regimens Containing Efavirenz, Nevirapine or Kaletra Are the Most Potent Options for Patients Starting Therapy (September 15, 2003)
[Archived Article]
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- Nevirapine Reduced Mother-to-Child Transmission Better Than AZT -- At 70 Times Less Cost (September 12, 2003)
[Archived Article]
In AIDS Treatment News, from AIDS Treatment News
- Substitution of Nevirapine, Efavirenz, or Abacavir for Protease Inhibitors in Patients With Human Immunodeficiency Virus Infection (September 11, 2003)
[Archived Article]
In The New England Journal of Medicine
- Scientists in Uganda Dismiss South African Claims About Safety, Efficacy of Nevirapine (August 19, 2003)
[Archived Article]
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Higher Than Recommended Dose of Nevirapine Needed for HIV Suppression in Children (August 7, 2003)
[Archived Article]
From aidsmap.com
- Low-Level Resistance and Minority Populations: Cross-Resistance Between Nevirapine and Efavirenz (August/September 2003)
[Archived Article]
Once an NNRTI-based regimen fails, no other NNRTIs will work any better, two studies suggest.
In Treatment Bulletin, from HIV i-Base
- IATEC Presents the 2NN Study Results (July 14, 2003)
[Archived Article]
To read PDF, click here
In STEP Ezine, from Seattle Treatment Education Project
- Nevirapine- Versus Efavirenz-Containing Three-Drug Regimens (July 14, 2003)
[Archived Article]
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Switch to Nevirapine From Protease Inhibitor Lowers Triglycerides and Maintains Viral Load Suppression (July 14, 2003)
[Archived Article]
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Does Viramune = Sustiva? (May/June 2003)
[Archived Article]
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
- Efavirenz More Durable Than Nevirapine, But CNS Toxicity Underestimated (April 29, 2003)
[Archived Article]
British researchers find that efavirenz works better over the long term, but that its psychiatric side effects persist a lot longer than previously thought.
From aidsmap.com
- Who Won 2NN? You (April 2003)
[Archived Article]
A summary of the 2NN study presented at CROI 2003.
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- Nevirapine Studied as Pre-Exposure Prophylaxis for HIV (February 25, 2003)
[Archived Article]
Early trials suggest a low dose of the drug may be safely used in HIV prevention.
From aidsmap.com
- Results of the 2NN Study: A Randomized Comparative Trial of First-Line Antiretroviral Therapy With Regimens Containing Either Nevirapine Alone, Efavirenz Alone or Both Drugs Combined, Together With Stavudine and Lamivudine (February 14, 2003)
[Archived Article]
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Lipid Changes in a Randomized Comparative Trial of First-Line Antiretroviral Therapy With Regimens Containing Either Nevirapine Alone, Efavirenz Alone or Both Drugs Combined, Together With Stavudine and Lamivudine (2NN Study) (February 13, 2003)
[Archived Article]
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Nevirapine Patient Assistance Program: Model for Better Administration? (November 22, 2002)
[Archived Article]
In AIDS Treatment News, from AIDS Treatment News
- Ethiopia Ready to Start Nevirapine Trials for AIDS Treatment (November 20, 2002)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Nevirapine and Vivid Dreams (September 12, 2002)
[Archived Article]
From Canadian AIDS Treatment Information Exchange
- Nevirapine During Labor and in the Neonate Significantly Improves Zidovudine Prophylaxis for the Prevention of Perinatal HIV Transmission: Results of PHPT-2 First Interim Analysis (July 12, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
- Promoting Prevention of Mother-to-Child Transmission of HIV Through the Viramune Donation Programme: A Model of Public-Private Partnership (July 10, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
- Switching Protease Inhibitors to Nevirapine, Efavirenz or Abacavir: A Randomized, Multicenter, Open-Label, Simplification Trial (July 10, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
- WHO and UNAIDS Continue to Support Use of Nevirapine for Prevention of Mother-to-Child HIV Transmission (March 22, 2002)
[Archived Article]
From UNAIDS
- Switching Protease Inhibitors to Nevirapine (NEV), Efavirenz (EFA) or Abacavir (ABA): A Randomized, Multicenter, Open-Label, Simplification Trial (February 28, 2002)
[Archived Article]
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- CHARM: A Phase III Open-Label, Randomized, Multi-Center Study to Evaluate the Efficacy and Tolerability of Adding Nevirapine and/or Hydroxyurea to a Triple Nucleoside-Based Antiretroviral Drug Regimen in Treatment-Naïve HIV-1-Infected Subjects (February 27, 2002)
[Archived Article]
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Effect of Nevirapine (NVP) for Perinatal HIV Prevention Appears Greatest Among Women With Most Advanced Disease: Subgroup Analyses of HIVNET 012 (February 27, 2002)
[Archived Article]
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- A Randomized Trial of Metabolic and Body Composition Changes in Patients Switching from PI-Containing Regimens to Abacavir (ABC), Efavirenz (EFV) or Nevirapine (NVP) (February 26, 2002)
[Archived Article]
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Nevirapine and Protease Inhibitor-Based Regimens in a Directly Observed Therapy (DOT) Program for Intravenous Drug Users (February 26, 2002)
[Archived Article]
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Comparison of Nevirapine Resistance Mutations in Women vs. Infants Receiving Single Dose NVP Prophylaxis to Prevent HIV-1 Vertical Transmission (HIVNET 012) (December 16, 2001)
[Archived Article]
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- Nevirapine Notes (November 2001)
[Archived Article]
In HIV Treatment ALERTS!, from The Center for AIDS
- Long-Term Follow-Up of Antiretroviral-Naive HIV-Infected Patients Treated with d4T and ddI (QD) and Nevirapine (BID or QD) in the VIRGO Study (October 29, 2001)
[Archived Article]
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO
- Rise in HDL Cholesterol Associated With Nevirapine Containing Antiretroviral Therapy in HIV-1 Infected Patients Is Sustained Over 48 Weeks of Treatment (October 29, 2001)
[Archived Article]
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO
- A Retrospective Cohort Study of the Durability of Antiretroviral Therapy Using Nevirapine versus Antiretroviral Therapy Using Protease Inhibitors (October 27, 2001)
[Archived Article]
In 39th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
- Retrospective Review of Nevirapine-Induced Hepatotoxicity in HIV/HCV Co-Infected Patients in a Community Health Center (October 27, 2001)
[Archived Article]
In 39th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
- Impact of HIV-1 Subtype on Women Receiving Single Dose Nevirapine Prophylaxis to Prevent HIV-1 Vertical Transmission (October 2, 2001)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Study Finds Women More Likely to Get Rash With Nevirapine Than Men (August 16, 2001)
[Archived Article]
From Canadian AIDS Treatment Information Exchange
- Metabolic and Anthropometric Changes Observed in HIV-Infected Patients Treated With Combivir (ZDV/3TC) Plus Nelfinavir or Nevirapine (A Substudy of the COMBINE Study) (July 10, 2001)
[Archived Article]
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Nevirapine-Containing Antiretroviral Therapy in HIV-1-Infected Patients Results in an Anti-Atherogenic Lipid Profile (July 10, 2001)
[Archived Article]
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Switching Protease Inhibitor (PI) to Nevirapine (NVP) Leads to a Better Lipid Profile Than Switch to Efavirenz (EFV) (July 10, 2001)
[Archived Article]
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Final 12-Month Results From the COMBINE Study: A Randomized, Open, Multicenter Trial Comparing Combivir Plus Nelfinavir or Nevirapine in Naive Patients (July 9, 2001)
[Archived Article]
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Nevirapine Containing Potent Antiretroviral Therapy Results in Ananti-Atherogenic Plasma Lipid Profile: Results From the Atlantic Trial (February 7, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Pharmacologic Characteristics of Efavirenz and Nelfinavir Associated With Virologic Response in HIV-Infected Children (February 5, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Adverse Effects Associated With Use of Nevirapine in HIV Postexposure Prophylaxis for Two Health Care Workers (December 6, 2000)
[Archived Article]
In Journal of the American Medical Association Research Letter
- More Data on the Comparative Efficacy of Protease Inhibitors Versus Non-nukes (October 10, 2000)
[Archived Article]
STEP's coverage of the 40th ICAAC Conference.
In STEP Ezine, from Seattle Treatment Education Project
- Inexpensive AIDS Drug Still Reduces HIV Transmission from Mother to Child After One Year (July 13, 2000)
[Archived Article]
From U.S. National Institute of Allergy and Infectious Diseases
- Sustained Virologic Suppression in Subjects Switched From Protease Inhibitors to Nevirapine (July 12, 2000)
[Archived Article]
In The XIII International AIDS Conference, from The Body PRO
- Studies Suggest Nevirapine Can Be Dosed Either Once or Twice Daily; Effective at Both High and Low Viral Loads (July 11, 2000)
[Archived Article]
In The XIII International AIDS Conference, from The Body PRO
- Viramune Affects Birth Control in HIV+ Women (March 31, 2000)
[Archived Article]
In STEP Ezine, from Seattle Treatment Education Project
- Selected Highlights From the 7th CROI: Nevirapine (Viramune) Plus AZT and 3TC (Spring 2000)
[Archived Article]
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- Nevirapine: One-Year Combination Results Published (April 3, 1998)
[Archived Article]
In AIDS Treatment News, from AIDS Treatment News
- Nevirapine Plus Two Nucleosides Exerts Durable Effect (April 1998)
[Archived Article]
In HIV Newsline, from San Francisco General Hospital
- Oral Contraceptive / Nevirapine Interaction Trial (March 6, 1998)
[Archived Article]
In AIDS Treatment News, from AIDS Treatment News
- Nevirapine Protects Chimpanzee Against HIV-1 Infection (January 1997)
[Archived Article]
In The 4th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
|
Advertisement
|
E-Mail
Glossary
Share